HER-2(humanepidermal growthfactorreceptor-2)是表皮生长因子受体家庭成员之一,在20%~30%的乳腺癌中过表达。大量研究表明HER-2过表达不仅提示乳腺癌的侵袭性更强,预后更差,还可作为赫赛汀(herceptin)这种人源化HER-2蛋白单克隆抗体治疗的重要靶标。最近研究表明,其表达水平亦影响乳腺癌对内分泌治疗的疗效。 HER-2 (humanepidermal growth factor receptor-2), a member of the EGFR family, is overexpressed in 20-30% of breast cancers. Numerous studies have shown that overexpression of HER-2 not only suggests that breast cancer is more aggressive and has a worse prognosis, but also as an important target for the treatment of herceptin, a monoclonal antibody to humanized HER-2 protein. Recent studies have shown that its expression level also affects the efficacy of endocrine therapy in breast cancer.